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Leonard W. Seymour10, Tingyan Shi11, Peter Van Loo 12, Christopher Yau13,14, Helen White15, Nina Wietek1, David N. Church 16,17,
David C. Wedge 17,18 and Ahmed A. Ahmed1,17,19
Cancer is a leading cause of death worldwide and, despite new targeted therapies and immunotherapies, many patients with
advanced-stage- or high-risk cancers still die, owing to metastatic disease. Adoptive T-cell therapy, involving the autologous or
allogeneic transplant of tumour-infiltrating lymphocytes or genetically modified T cells expressing novel T-cell receptors or chimeric
antigen receptors, has shown promise in the treatment of cancer patients, leading to durable responses and, in some cases, cure.
Technological advances in genomics, computational biology, immunology and cell manufacturing have brought the aspiration of
individualised therapies for cancer patients closer to reality. This new era of cell-based individualised therapeutics challenges the
traditional standards of therapeutic interventions and provides opportunities for a paradigm shift in our approach to cancer
therapy. Invited speakers at a 2020 symposium discussed three areas—cancer genomics, cancer immunology and cell-therapy
manufacturing—that are essential to the effective translation of T-cell therapies in the treatment of solid malignancies. Key
advances have been made in understanding genetic intratumour heterogeneity, and strategies to accurately identify neoantigens,
overcome T-cell exhaustion and circumvent tumour immunosuppression after cell-therapy infusion are being developed.
Advances are being made in cell-manufacturing approaches that have the potential to establish cell-therapies as credible
therapeutic options. T-cell therapies face many challenges but hold great promise for improving clinical outcomes for patients with
solid tumours.
British Journal of Cancer (2021) 124:1759–1776; https://doi.org/10.1038/s41416-021-01353-6
BACKGROUND
Personalised, or precision, medicine aims to identify the optimal
treatment for each patient in order to maximise benefit and
minimise toxicity. In the context of cancer treatment, advances
in genomics have enabled the identification of germline and
somatic genomic alterations that can be matched to therapeu-
tics on an individual patient basis1—in some cases, such as the
use of imatinib for the treatment of chronic myeloid leukaemia
to great effect.2 However, most cancer genomes lack driver
mutations for which a molecularly targeted agent is available.3
The unprecedented results obtained using novel cancer
immunotherapies such as immune checkpoint blockade (ICB)
have revealed the potential of leveraging the immune system in
cancer treatment.4 Unfortunately, despite durable responses in a
subset of patients, particularly those with melanoma or non-
small cell lung cancer (NSCLC),5–7 most patients do not respond
to the immunotherapies in current use;8,9 in fact, it has been
estimated that responders to ICB might constitute around only
13% of cancer patients.10
Advanced therapy medicinal products (ATMPs) hold promise to
transform cancer treatment11—cell-based vaccines,12,13 engi-
neered T cells14 or autologous tumour-infiltrating lymphocytes
(TILs), for example, represent highly personalised modes of cancer
treatment. However, the application of cell-therapy approaches to
large numbers of cancer patients presents major challenges, as
good manufacturing practice (GMP) is a complex and expensive
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process. Moreover, to improve the effectiveness of ATMPs, we
need to gain a better and more comprehensive understanding of
the interaction between cancer and the immune system. This
review will discuss what we believe are the three most important
areas for advancing the field of personalised cell immunothera-
pies: cancer genomics; cancer–immune system interactions; and
ATMP manufacturing. We will focus on discussing the promises
and challenges of each area for solid cancers and highlight
potential factors for improvement, particularly in the field of T-cell
therapy (Box 1).
ATMPS IN THE ERA OF PERSONALISED MEDICINE
An ATMP can be a gene therapy medicinal product (e.g.
Holoclar®, a stem-cell treatment used for limbal stem-cell
deficiency in the eye); a somatic cell therapy medicinal product
(e.g. TILs for the treatment of tumours); a tissue-engineered
product (e.g. anti-CD19 CAR-T therapies); or a combination of
any of the above (Table 1). Personalised cell-therapy treatments
are a type of ATMP, manufactured specifically for each patient
using their own cellular material (e.g. immune cells). They are
intended as long-term or permanent therapeutic solutions to
acute or chronic human diseases such as cancer. The ability to
extract and grow immune cells—in particular, T-cells—in vitro
paved the way for the use of adoptive cell transfer (ACT; the
transfer of cells to a patient) in cancer immunotherapy.15
Broadly, ACT can be carried out using three different T-cell
approaches. In the first, TIL-ACT, endogenous TILs are expanded
ex vivo from a patient’s tumour before being infused back into
the patient. The second approach uses T-cell receptors (TCRs)
that have been engineered to recognise specific tumour
antigens, although this approach is limited to major histocom-
patibility complex (MHC)-expressed antigens. Chimeric antigen
receptors (CARs) comprise an extracellular antigen recognition
domain, a transmembrane domain, and a cytoplasmic signalling
domain, and so can recognise a variety of cell-surface antigens,
by contrast, independently of MHCs.16,17
Scientific advances throughout the entire pipeline from
biopsy to the manufacturing of cell therapy products have
made ACT potentially more accessible to growing numbers of
patients. Accordingly, cell therapy trials in cancer are steadily
increasing in number worldwide, with the second largest
number of active trials (after ICB) in the immuno-oncology
space.18 However, despite ~90% of cancer incidences globally
being caused by solid tumours, only around half of these trials
are targeting solid tumours, and they have rarely been extended
to non-melanoma cancers, due to a lower immunogenicity of
these tumours.19–23 Moreover, although clinical trials using cell
therapy products directed against cancer neoantigens derived
from somatic mutations hold promise, evidence of success is still
limited to case reports of patients with particular tumour types
such as cervical cancer,24 cholangiocarcinoma,25 metastatic
melanoma,26–29 colorectal cancer,30 breast cancer31 and thy-
moma.32 Further studies are thus needed to advance the
potentially curative approach of ACT.
CANCER GENOMICS
The decreasing costs and technological advances in massively
parallel sequencing techniques have enabled the identification of
somatic mutations in cancer on a large scale and facilitated the
clinical implementation of genomic medicine.33–35
Neoantigens and personalisation of therapy
The cellular immune response to cancer largely depends on T cells
that specifically target cancer/testis antigens (CTA) or cancer
neoantigens that are derived from somatic genomic alterations
that lead to the expression of immunogenic neoepitopes.36–38 In
this article, we focus on cancer neoantigens, which result from
genomic perturbations, exhibit entirely novel amino acid
sequences and, importantly, are rarely shared among patients.
These mutant peptides that bind to human leukocyte antigen
(HLA) class I or HLA class II molecules are capable of generating a
robust and durable immune response, and high mutational and
predicted neoantigen load are significantly associated with
improved progression-free and overall survival in melanoma
patients treated with TIL-ACT.39 Furthermore, evidence from
melanoma patients treated with TILs suggests that the evoked
immune response comprises both CD4+ and CD8+ T cells specific
for mutant epitopes,25,27,40 with cases of off-target immune
response against the wild-type, non-mutated peptide being
exceptionally rare.41,42
The combination of genomics and cellular immunotherapy
permits the identification of somatic alterations and the prediction
of potential neoantigens that could be utilised as targets for
therapy by vaccination, adoptive TIL transfer, or engineered T-
cells.42,43 The pipeline for neoantigen-directed cell-therapy is
presented in Fig. 1a. Significant efforts have been made to
advance the individual steps, particularly the detection
of mutations and prediction of neoepitopes, which is
principally determined by the probability that mutant peptides
bind HLA-I.44–47 The current state-of-the-art and challenges of
bioinformatic analysis of the cancer mutanome for ACT has been
extensively reviewed elsewhere.47,48
Tumour heterogeneity and evolution
Data from international collaborative studies have shed light on
many aspects of cancer genomics and cancer evolution, which
could potentially inform the implementation of bioinformatics
pipelines for cancer mutanome discovery.33,49 Genomic studies
have demonstrated how tumour heterogeneity and evolution
drive resistance to systemic anti-cancer and targeted therapy50–52
such as epidermal growth factor receptor (EGFR) amplification and
mutations in the MET or PIK3CA gene resistance in EGFR+
tumours after EGFR inhibitors treatment.53 Cancer heterogeneity
similarly represents a pivotal challenge for the development of
neoantigen-directed-TIL therapies.54
The expansion of TILs from multiregional biopsy samples, from
distinct cancerous lesions within the same patient or from
different regions within the same tumour, could give a more
accurate snapshot of intratumour heterogeneity at a single time-
point (Fig. 1b) and, therefore, enable the more successful design
of TIL therapies targeting a substantial proportion of tumour cells
in any given cancer.55 Neoantigen-specific CD8+ and CD4+
lymphocytes have also been detected in peripheral blood,56–58
which could overcome the problem of limited specimen
availability in certain tumours. However, the low levels of these
neoantigen-specific lymphocytes from peripheral blood and their
discordant TCR repertoire compared with TILs collected from the
same patients could represent a challenge for their suitability
for ACT.59
Clonal mutations and neoantigen quality. A 2020 publication
looking at the timescales of tumour development showed that
‘first driver’ events seemingly occurred up to decades before
Box 1 Generation of this conference report
This Oxford meeting ‘Advanced Personalised Therapeutics in Solid Cancers’ in
February 2020 convened experts to discuss our current understanding of
challenges in advance medicinal therapeutic products (ATMPs) in the treatment
of solid cancer. The emphasis was on discussing challenges in the field of cancer
genomics, cancer–immune system interaction and manufacturing of ATMPs. The
idea of summarising the outputs from the meeting in a report was proposed and
unanimously approved before the meeting. Following the talks, at the end of
each topic session, an open discussion with all meeting participants was held to
collate ideas and future perspectives. A draft statement was then circulated to all
authors for feedback and refinement, leading to agreement with the views
expressed in this manuscript.
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diagnosis, demonstrating how cancer genomes are shaped by a
near-lifelong process of somatic evolution.60 The evolution of
most cancers usually involves common early mutations in cancer
driver genes, followed by diverse trajectories generated by
individually rare driver mutations, and by copy number altera-
tions.60 Intriguingly, for some cancers, genomic sequencing is
unable to identify driver mutations.49 A notable advantage of
neoantigen-driven immunotherapy is that the issue of whether or
not a mutation in a cancer gene occurs is irrelevant; what is
important is that the mutation is clonal—that is, it is shared by all
cancer cells—which increases the number of therapeutic targets
in a way that is not feasible using traditional small-molecule
targeted therapies. Predicting neoantigens that are shared
amongst a substantial proportion of the target cell population is
vital for the success of ACT, irrespective of which gene a mutation
resides in. Mutations that occur early are important to consider for
immunotherapy as they would be clonal and are, therefore, at the
trunk of a tumour’s phylogenetic tree61–63 (Fig. 1b) and might
consequently generate a more effective anti-cancer T-cell
response compared with later mutations (subclonal) that are
limited to subpopulations of cancer cells.64–66 The identification of
clonal mutations relies on the accurate computation of the
prevalence of mutations in a tumour.67 This is not a trivial task and
is often confounded by normal cell contamination, substantial
heterogeneity and copy number alterations.68 However, advances
in sequencing and computational technologies, particularly in the
field of linked-read methods, have enabled improved estimation
of the prevalence of mutations by incorporating phase informa-
tion. This allows the alleles identification on maternal and paternal
chromosomes which is important for understanding gene
expression patterns in tumours.69,70 Whether subclonal neoanti-
gens developing in a rapidly evolving tumour or in response to
treatment pressure71 can actively distract the immune response
from effectively targeting clonal neoantigens is unclear. Thus,
therapeutic efforts might need to be oriented toward the
targeting of multiple clonal neoantigens to optimise disease
control and minimise the potential for immune escape.
Predicting neoantigens beyond somatic mutations. Another key
challenge is that only a few predicted neoantigens encoded by
somatic non-synonymous mutations are actually immuno-
genic.55,72–74 Therefore, expanding the search for immunogenic
antigens to include different categories of genomic alterations
beyond non-synonymous mutations is essential. Single-nucleotide
variants (SNVs), insertions and deletions (indels) causing
frameshifts, chromosome alterations and splice variants could all
potentially generate neoantigens (Fig. 1c).75 Data from cancer
genomics studies also shed insights into the timing of acquisition
of structural variants and76,77 copy number gains78–80 and the
incidence and timing of punctuated events (such as chromo-
thripsis, chromoplexy, kataegis) in cancer evolution.49,81 Owing to
their high prevalence in cancer genomes and their near absence
in healthy tissues, complex chromosomal rearrangements repre-
sent an exciting potential target for the identification of
neoantigens. Frameshifts resulting from indels, if they evade
nonsense-mediated decay, have been shown to generate
approximately three times as many high-affinity neoantigens as
non-synonymous SNVs.82,83 Interestingly, mitochondrial-localised
peptides were shown to induce a more robust immune response
than cytoplasmic peptides, owing to their increased stability,
indicating that the subcellular localisation of peptides might be
important in determining their immunogenicity, which could
potentially be exploited during the identification of predicted
neoantigens.84
As shown in Fig. 1a, the neoantigens predicted from genome
sequencing data (whole-genome and exome sequencing) are
usually filtered by gene expression (RNA-seq) to assess the
expression (yes or no) of that given gene. However, single-cell
transcriptomic sequencing (scRNA-seq) data from ovarian and
lung cancer documented the presence of non-genetic hetero-
geneity amongst cancer cells, with evidence of remarkable
plasticity and capability of transitioning from one cell state to
another.85–88 This phenomenon might be relevant for the
selection of cancer neoantigens. For example, knowing the
predominant cellular state of a tumour (e.g., stemness pro-
gramme88) would make it possible to prioritise neoantigens that
are encoded by genes that are expressed in that particular cell
state. Not surprisingly, promoter hypermethylation has been
shown to affect the expression of ~23% of the predicted
neoantigens studied in a large cohort of lung cancer,89 high-
lighting the occurrence of transcriptional repression mechanisms
in cancer and their potential significance in neoantigen
identification.90
Improving the prediction of neoantigen immunogenicity. Once
potential neoepitope-generating mutations have been identified,
T cells are assessed for their reactivity against tandem minigenes
(TMGs) or peptides containing the potential neoantigens (Fig. 1a).
Challenges in determining the anti-tumour reactivity of
neoantigen-specific T-cells have been reviewed elsewhere47 but,
Table 1. Advanced therapeutic medicinal products (ATMPs).
Product category Definition Examples
Gene-therapy medicinal
product (GTMP)
Contain genes that lead to a therapeutic, prophylactic or
diagnostic effect. They work by inserting ‘recombinant’
genes into the body, usually to treat a variety of diseases,





Patient-derived cellular gene therapy products
Somatic-cell therapy medicinal
product (SCTMP)
Contain cells or tissues that have been manipulated to
change their biological characteristics or cells or tissues
not intended to be used for the same essential/original
functions in the body.
Products containing or consisting of animal cells or
tissues
Other autologous and allogeneic cells therapies
Xenogeneic living cells
Stem cells and stem cell-derived products
Tissue-engineered
product (TEP)
Contain cells or tissues that have been modified so they
can be used to repair, regenerate or replace human tissue.
Products containing or consisting of animal cells or
tissues
Products might also contain additional substances, such
as cellular products, biomolecules, biomaterials, chemical
substances, scaffolds or matrices
Products for cartilage or cardiac defects, among others
Stem cells and stem cells-derived products
Combined ATMP A combination of the above None as yet
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in addition to technological limitations, it is important to note that
not every specific neoepitope gives an immune response.91 An
inherent bias in this pipeline is that we can only test the
immunogenicity of the neoepitope-generating mutations that we
are able to predict bioinformatically. In addition, neoantigen
overlap predictions of the top 100 ranked peptide-bound MHCs
from the same tumour samples between different teams of a
global community has been shown to be low (less than 20%) in
the majority of the cases. This lack of consensus might be partially
driven by differences in epitope filtering and/or ranking between
the different teams and suggest that efforts to harmonize
neoantigen-prediction will be necessary for future clinical cross-
comparison of neoantigen-based TIL trials between different
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Fig. 1 Targeting cancer neoantigens using cell therapy. a Using autologous tumour-infiltrating lymphocytes in autologous cell transfer. The
resected specimen is divided into multiple tumour fragments that are individually grown in IL-2 for 7–10 days. For the ‘non-specific’ TIL
therapy (dashed line) the individual cultures are then moved to a rapid expansion protocol before reinfusion into patients. Neoantigen-TIL
therapy involves the sequencing of exomic or whole-genome DNA from tumour cells and healthy cells to identify tumour-specific mutations,
before RNA-sequencing is used to check for the expression of mutations. Corresponding minigenes or peptides encoding each mutated
amino acid are synthesised and expressed in or pulsed into a patient’s autologous antigen-presenting cells (APCs) for presentation in the
context of a patient’s HLA. Individual mutations responsible for tumour recognition are identified by analysing activation of a T-cell co-
stimulatory marker, such as 41BB/CD137 (CD8+ T cells), in response to cognate target antigen recognition. b Genetic and genomic
heterogeneity and evolution of clonal populations. Upper panel: Genetic and phenotypic variations are observed between tumours of
different tissues (inter-tumour heterogeneity). Within a tumour, subclonal diversity can be observed (intra-tumour heterogeneity, different
colours of tumour clones). Clonal alterations occurring early in tumorigenesis are represented by the blue trunk of the phylogenetic tree
(truncal mutations); later alterations could be shared by tumour cells in some regions of the tumour (light blue and pink branches of the tree)
or present in only one region of the tumour (yellow branches of the tree) in a branched cancer evolution model. Tumour subclones can also
show differential gene expression due to non-genetic heterogeneity. Lower row: Unique clones (represented by different colours) emerge as a
consequence of accumulating driver mutations in the progeny of a single most recent common ancestor cell. Ongoing linear and branching
evolution results in multiple simultaneous subclones that can individually give rise to episodes of disease relapse and metastasis. c Overview
of the neoantigen landscape. The sources of potential neoantigens for HLA class I ligands are shown. In tumours, mutated or aberrantly
expressed proteins are processed via the proteasome into peptides. The cross-priming abilities of peptides are also linked to non-genetic
factors such as protein stability, which can be modulated by several factors, including their localisation in the mitochondria. These peptides
can be loaded onto HLA class I molecules and might or might not elicit a CD8+ T-cell response, depending on several factors, including
peptide sequence or T-cell receptor (TCR) sequences. In general, most of the neoantigens derived from single-nucleotide variants gain their
immunogenicity through altered amino acids involved in direct T-cell contact.
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being positively selected for during tumorigenesis, thus empha-
sising the importance of CD4+ T cells in anti-tumour immunity,93
the computational prediction and analysis of HLA-II remains an
ongoing challenge owing to the highly polymorphic nature of the
HLA-II and poorly characterised endosomal HLA-II peptide
processing, which limits the development of HLA-II peptide
processing algorithms.45,94,95 Furthermore, despite the core
binding motif of both HLA molecules comprising peptides of
approximately nine amino acids, HLA-II-restricted ones have a
wider length range (11–20 amino acids) compared with HLA-I-
restricted ones (8–11 amino acids)96 which can make bioinfor-
matics prediction task challenging.
The use of mass spectrometry for the direct discovery of
tumour-specific HLA peptides (immunopeptidomics) holds pro-
mise for defining targets for immunotherapy (Table 2). Promises
and challenges of this approach have been reviewed else-
where.97,98 The use of data-driven machine-learning approaches
to leverage information from established sets of HLA-I and,
notably, HLA-II ligandomic data has provided new hope for
improving the ability to predict a broader range of neoantigens,
including those derived from post-translational modification as
well as from the cancer-specific translation of products arising as a
consequence of alternative splicing and intron retention, RNA
editing, novel open reading frames and endogenous retrovirus
elements99–105 (Fig. 1c). The need to incorporate these ‘unconven-
tional’ tumour antigens into current approaches for predicting
neoantigens has been reviewed.38 The increase in available data
on peptide immunogenicity and TCR binding prediction along
with machine-based learning extrapolation could have the power
to improve the quality of neoantigen identification106 by
incorporating structural and associated physical principles into
approaches for evaluating immunogenicity107 and to potentially
identify immunogenic hotspots for directed neoantigen target-
ing.108,109
In conclusion, despite being reliable and extremely promising,
personalised immunotherapy that targets unique mutations faces
many challenges. Apart from the technical and logistical hurdles
for this highly personalised approach, which will be discussed
below, a better understanding of cancer trajectories from
preneoplastic lesions to invasive cancer and of the simultaneous
pressure of the immune system (immunoediting) is warranted to
improve the identification of neoantigens.65
CANCER–IMMUNE SYSTEM INTERACTIONS
Cancer immunoediting and immunoevasion
Scientific advances over the past decades have demonstrated
that the immune system can paradoxically both constrain and
promote tumour development and progression. This process is
referred to as cancer immunoediting and, in its most complex
form, involves three phases—elimination, equilibrium and
escape—that ultimately result in the advent of immune-
resistant variants.110,111 The constant pressure from the adaptive
immune system coupled with the genetic instability of tumour
cells can select for tumour subclones with reduced immuno-
genicity that can evade immune recognition and destruc-
tion.112–114 The immunological control of tumour progression
and sculpting of tumour genomes has been shown in several
solid cancers, with tumour regions that harbour the highest
levels of immune infiltrates exhibiting the lowest cancer cell
Table 2. Glossary of terminology.
Neoantigen in silico peptide prediction and prioritisation The indirect identification of candidate neoantigen-generating peptides derived from
genome sequencing uses algorithms to identify those peptides that are more likely to be
presented on HLA-I based on biochemical and biophysical properties. Algorithms for
HLA-I-restricted peptides are less accurate for less frequent HLA-I clonotypes but overall
more reliable than HLA-II predictors. Their performance depends on the accuracy of the
used algorithms, which have shown low concordance in large studies
Neoepitopes and neoantigens Neoepitopes indicate amino acid sequences that are presented by MHC molecules on a
cell surface. Neoantigens refer to epitopes presented by a cell that contains sufficient
MHC-peptide expression and induces a T-cell response
LC-MS/MS-based immunopeptidomics Unbiased, direct identification of naturally presented HLA-bound peptides by liquid
chromatography mass spectrometry. It also allows the identification of post-
translationally modified peptides. Technical limitations still hinder it as it requires a
discrete amount of tumour tissue and could be biased towards detecting the more
abundant peptides. Also, it relies on the HLA expression of tumour cells
Techniques for identifying the immunogenicity of the
predicted neoantigens
The experimental identification of which candidate neoantigens can generate an anti-
tumour T cell response. Traditional methods involve the direct expression of putative
neoantigens (with minigenes or peptides) within HLA-genotype matched antigen-
presenting cells. These cells are then incubated with tumours to identify reactive T-cell
populations by interferon (IFN)-γ enzyme-linked immune absorbent spot (ELISPOT),
intracellular cytokine staining or using multi-colour-labelled major histocompatibility
complex (MHC) tetramers for multiplex flow cytometry
MHC tetramers Complexes of four MHC molecules associated with a specifically predicted neopeptide
and bound to a fluorochrome
Tandem minigenes A string of minigenes encoding the mutated amino acid flanked by 12 amino acids on
their N- and C-termini
T-cell receptor (TCR) repertoire This refers to all of the unique TCR genetic rearrangements within the adaptive immune
system at a given time point. Evenness, richness, and diversity (typically used to describe
ecological communities and their interactions with their environment) describe the TCR
profile. Clonal evenness refers to the distribution of TCR to describe clonal expansion;
clonal richness refers to measuring the number of clones with unique TCRs. Clonal
diversity entails the distribution of TCR, taking into account both evenness and richness
Techniques for identifying the TCR repertoire Bulk next-generation sequencing allows the high-throughput sequencing of α and β
chains of TCR but is limited by the inability to pair α and β sequencing. Single-cell
technologies can provide sequence information on paired α and β chains of individual
cells and their association with the same cells’ gene-expression profile
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clonal diversity, which is likely to be a reflection of neoantigen
depletion and loss of heterozygosity (LOH) at the HLA loci.115,116
The timing of initiation of immunological sculpting is an
important question in cancer biology. The number of expanded
TCRs found ubiquitously across all tumour samples in early-
stage lung cancer or paired metastatic breast and ovarian cancer
implies that some level of immune surveillance directed against
clonal neoantigens can be initiated early and maintained
through all levels of cancer development, including metastatic
progression.115,117,118 However, as is evident through the lack of
cancer cell elimination, immune escape mechanisms capable of
preventing T-cell mediated death might be an extremely early
event in cancer evolution.
Potential immune escape mechanisms. The immunogenicity of
neoantigens has been challenged. A study using data from The
Cancer Genome Atlas (TCGA) showed that neoantigen depletion,
detected using HLA affinity predictions, is weak or absent in the
untreated cancer genome overall.119 This observation is consistent
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Fig. 2 T cell conditioning to overcome the immunosuppressive tumour microenvironment. a Immuno-evasion mechanisms in the tumour
microenvironment. A representative example of an ‘excluded’ (cold) T-cell tumour is shown. Some of the most studied immune cells along
with their ligand–receptor and secreted growth factors (chemokines and cytokines) known to promote immunoevasion are shown. In the
black box, examples are given of cancer genetic alterations linked to an immuno-evasive tumour microenvironment (ADE adenosine, ARG1
Arginase 1, CAFs cancer-associated fibroblasts, DC dendritic cell, IL interleukin, iNOS inducible nitric oxide synthase, KYN: kynurenine, MDSC
myeloid-derived suppressor cells, NO nitric oxide, PGE2 prostaglandin E2, ROS reactive oxygen species TAMs tumour-associated macrophages,
TGF-β transforming growth factor-β, Treg regulatory T cell, VEGF vascular endothelial growth factor). In the black box are highlighted genetic
mechanisms linked to a cold TME. b T cell exhaustion in solid tumours. A representative image of transitions from an effector (Teff) to an
exhausted (Tex) T cell is shown. Chronic antigen exposure and the TME pressure promote the activity of transcription factors (such as NFAT,
TOX), which increases the expression of exhaustion-associated molecules such as PD1, LAG3, and TIM3, and the downregulation of effector
cytokines such as IFNγ, GrzB and IL-2 sensitivity. GrzB Granzyme B, IL2 interleukin-2, TME tumour microenvironment, TRM tissue-resident
memory. c Potential interventions to increase TIL efficacy during the expansion of T cells for ACT. The tumour microenvironment (TME) can be
modulated ex vivo with different drugs (such as epigenetics, immunometabolic drugs) or interleukins (e.g. IL-2, IL-15) to boost the growth and
activation of tumour-infiltrating lymphocytes, to increase the number of neoantigens (epigenetic drugs) or to preferentially expand TIL-
specific subtypes such as tissue resident memory T cells (TRM-TILs). CRISPR–Cas9 ribonuclear protein complexes loaded with single-guide
RNAs can be electroporated into TILs or normal T cells for gene editing. Shown here is an example of deletion of TCRs (off-the-shelf T cells)
and of inhibiting immune checkpoint receptors such as programmed death 1 (PD-1) in T cells. Protein engineering can be used for the
creation of orthogonal IL-2–IL-2 receptor pairs, which consist of a mutant orthogonal IL-2 cytokine (oIL-2) and mutant IL-2 receptor (oIL-2R)
that interact specifically with each other but do not interact with their wild-type counterparts. SMAPs (supramolecular attack particles) can be
produced in vitro and grafted to relevant specific TCRs for adoptive transfer.
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across 29 cancer types are not subject to selection and that only a
minority of mutations (∼5%) were positively selected when
evaluating the selection pressures exerted on mutant somatic
cancer alleles (nonsense versus missense mutations).120 Similarly,
few differences in the immunoediting of clonal neoantigens were
seen in a large cohort of lung cancer patients.89 Therefore, either
only very few predicted driver neoantigens are immunogenic, or
driver mutations possess the ability to evolve efficient early
immune evasion mechanisms. This could potentially be linked to
individual variation at the HLA locus,121 LOH in the HLA
region or by inducing other mechanisms such as amplification
of the immune checkpoint molecule programmed death
ligand-1,119,122,123 as was demonstrated by comparing preinvasive
lesions of the lung that were immune-competent (and therefore
regressed) with those that progressed.124 Additionally, hyper-
methylation of the HLA region was also commonly observed124
(Fig. 2a).
Interestingly, several studies have demonstrated the wide-
spread appearance of cancer mutations in healthy tissues,
including the oesophagus, skin, liver, lung, endometrium and
colon.125–130 The concept of normal cell mutagenesis has
revolutionised our understanding of cancer development, as
driver mutations are not only limited to carcinogenesis but are
also common events throughout life, occurring as early as
embryogenesis.131 The presence of these widespread mutations
in healthy tissue might also influence our understanding of cancer
immunotherapy and cell-therapy development, as they could
provide insight into those potential neoepitopes against which
the immune system has been already tolerized (e.g. neoepitopes
generated by mutations in cancer genes early in life). This might
guide future prioritization of neoepitopes for neoantigen-based
therapies.
Another explanation for the lack of negative selection of
mutated cells is that the pervasive presence of driver mutations in
healthy tissue starting even at the embryonic level is tolerated by
the immune system until other insults, such as the potential
invasion of the basal epithelial layers or metabolic changes,
occur.120 In addition, some cancer-associated driver mutations
have been reported to attenuate immune responses. For example,
mutations in the genes KRAS and BRAF or other mutational
activations in components of the mitogen-activated protein kinase
(MAPK) pathway can decrease the transcription of HLA class I
molecules as well as the expression of other genes encoding
molecules that are essential for peptide loading.132–135 Whether
and how these driver mutations in healthy tissues are surveyed,
selected and removed by the immune system is a crucial
biological question and could significantly enhance our under-
standing of cancer–immune interactions and the immunogenic
properties of a given mutation.
Increasing our understanding will entail re-focusing on the
importance of tissue-specific immunity/‘structural immunity’136
and how each organ’s immune system can affect cancer
development and treatment.137,138 In the same way that
comprehensive DNA profiling of tumours has revealed the
genetics of cancers and the significant variation amongst tumours
and individual patients,49,60,81,139,140 knowing the difference in the
immunological composition and peripheral fitness selection of
T cells141 between different organs might provide insights into the
role of the early and late events of immunosurveillance in cancer
development in a given tumour microenvironment (TME).142,143
The tumour microenvironment and TILs
T-cell infiltration into the TME has been extensively demonstrated
to be clinically relevant, with the quantity, quality and location of
the immune infiltrate (known as the ‘immune contexture’) of
cytotoxic and memory T cells within the solid tumour accurately
predicting clinical outcome144–147 as well as a positive response to
ICI therapy.148,149 The density of the T-cell infiltrate has been
linked to cancer genomic characteristics, with tumours that are
genetically more heterogeneous showing less immune infiltra-
tion.150,151 Analysis of synchronous metastases in patients with
melanoma has revealed not only genetic heterogeneity but also
immune-infiltration heterogeneity in terms of different immune
cell types and T-cell clonality between different sites in the same
patient.152
T-cell infiltration, activation and exhaustion. Relatively little is
known about the cancer-intrinsic mechanisms, alterations and
oncogenic signalling programmes that underlie TME heterogene-
ity.153 The dysregulation of specific pathways, such as WNT–β-
catenin signalling, and tumoral amplification of genes that encode
proteins associated with immunosuppression, such as PD-L1, the
arachidonate lipoxygenases, and indoleamine-2,3-dioxygenase-1
(IDO-1) and IDO-2, have been linked with low T-cell infiltration and
lower cytolytic activity.154–156 The association between WNT–β-
catenin signalling and TME modulation is further supported by the
observation that immune-excluded tumours are enriched for
mutations in negative regulators of the WNT–β-catenin pathway
in treatment-naive high-grade serous ovarian cancer157 (Fig. 2a).
Several biochemical pathways and cell types in the TME have
been reported to lead to a decrease in T-cell infiltration (T-cell
homing) and activation, as well as increased T-cell exhaustion,
thereby increasing immunoevasion in different tumour types158–161
(Fig. 2a). It appears evident that an understanding of the biology of
how the TME shapes the pattern and levels of immune-cell
infiltration and exhaustion will be a key factor for the success of
ACT.162 This understanding could provide the biological knowledge
to pharmacologically modulate the key pathways of immunoevasion
prior to or during the administration of ACT to the patients.
Furthermore, drugs could be administered to tumour fragments
ex vivo during the manufacturing of the cell product to increase TIL
expansion and activation. In addition, the cell product could be
engineered to enhance persistence and activation in vivo.163 These
aspects will be discussed in further detail below.
Therapeutic approaches to increase T-cell infiltration. The ability of
the TME to show a myriad of pathway redundancies and develop
metabolic adaptations precludes, from a clinical point of view,
multiple simultaneous targeting to avoid patient toxicity. How-
ever, the importance of establishing inflammation in the TME and
thus overcoming immune exclusion and increasing T-cell homing
in solid tumours (turning the tumours ‘hot’) has stimulated
research into the discovery of new therapeutic options.164,165 Such
an approach will be crucial for ACT success as the presence of TILs
(indicative of an inflamed tumour) is a prerequisite for TIL
expansion. Radiotherapy, which is capable of inducing immuno-
genic cell death by exposing tumour-associated antigens/neoanti-
gens that can be recognised by antigen-presenting cells (APCs)166
and then presented to CD8+ T cells, is currently being tested in
clinical trials in combination with ICB.167
The combination of ICB and ACT has been shown to be feasible
and safe in patients with ovarian cancer.168 Another interesting
strategy to render tumours ‘hot’ is the use of oncolytic viruses—
native or genetically modified viruses that selectively infect and
replicate within tumour cells, eventually leading to tumour cell
lysis.169 Direct injection into cancer cells of the oncolytic
virotherapy agent talimogene laherparepvec, which is also
engineered to produce granulocyte/macrophage colony-
stimulating factor (GM-CSF) to induce an immune response,
increased T-cell infiltration and the response to ICIs in melanoma
patients.170 Similarly, administration of a dendritic cell (DC)-based
vaccine has been shown to increase T-cell infiltration and induce
T-cell responses to autologous tumour antigens in ovarian cancer
whole cell lysate.166 These therapeutic options could constitute a
priming step to stimulate an immune response and thus create
the basis for T-cell interrogation of neoantigens for subsequent TIL
Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti et al.
1765
therapy, particularly in those patients whose tumours have a low
number of TILs.171
These therapies (virotherapy, low-dose radiotherapy) can also
induce a systemic increase of chemokines (such as CCL2 and CCL5)
known to promote T-cell homing and T-cell infiltration172–174
(Fig. 2b). Indeed, a 2019 publication reported that the cooperation
of chemokines such as chemokine ligand 5 (CCL5), which is
constitutively expressed by tumour cells, with IFN-γ-inducible
chemokines such as chemokine ligand 9 (CXCL9), plays a key and
universal role in the orchestration of T-cell responses in tumours
and facilitates the establishment of the T-cell-inflamed pheno-
type.175 The loss of tumour-intrinsic chemokines (such as CCL5, for
example) that support T-cell recruitment is a common mechanism
of immunoevasion. These results could open opportunities for the
manipulation, using genome-engineering techniques, of these
T-cell homing ligands in expanding TIL populations to enhance
T-cell engraftment.
The preferential expansion of TIL subtypes. The intrinsic capacity
of intratumoural T cells to recognise adjacent tumour tissue can
be rare and variable (∼10% in the case of melanoma, ovarian and
colorectal cancer CD8+ TILs41,176); the majority of TILs are
bystander T cells.177 Thus, strategies to enrich a predefined
neoantigen-specific subpopulation or tumour-specific cells would
increase the chances of obtaining a final TIL product with
adequate tumour reactivity as well as persistence in vivo.178,179
The preferential expansion, via cytokine modulation or using
bioengineering materials, of specific T-cell subtypes, such as the
tissue-resident memory (TRM) T cells, is an interesting
approach.180,181 TRM T cells are particularly attractive for TIL-ACT
as they are associated with better survival outcomes in many solid
tumours and have an inherent capacity to home, owing to the
expression of specific integrins on their cell surface.182–186
Moreover, the CD8+PD1+CD103+ TRM subpopulation represents
the predominant proportion of TILs with expanded intratumoural
ubiquitous TCRs (thus recognising clonal neoantigens), and these
TCRs been demonstrated to be expressed on tumour-reactive
T cells in lung cancer patients.187
As mentioned, the success of ACT depends not only on the
homing capability of the cell product, but also on additional
specific properties such as the differentiation state and ability to
persist in vivo, along with the capacity to exert effector functions
against cancer cells in the host (Fig. 2b). Therefore, a better
understanding of the physiological mechanism that couples cell
expansion and differentiation in T cells could improve the efficacy
of ACT.188 An increased understanding might facilitate in vitro
strategies to increase the percentage of tumour-reactive stem-like
TILs, for example, which have been shown to be capable of self-
renewal, expansion, persistence and a superior anti-tumour
response in patients with melanoma.189
Maintaining T-cell activity/responses. The persistence of high
amounts of antigen and the immunosuppressive nature of the
TME push the majority of cancer-specific T cells towards an
exhausted phenotype176,177,190 (Fig. 2c). As these cancer-specific
T cells become less responsive to interleukin-2 (IL-2), which
mediates T-cell expansion, they might become diluted by
bystander T cells during the process of expansion in TIL-ACT,
with an overall loss of TCR repertoire.15,191,192 However, despite
their functional impairment, it is widely appreciated that
exhausted T cells are often tumour-specific and can still retain
some control over tumour growth, as shown by the great clinical
effect of blocking programmed death protein 1 (PD-1) or
programmed cell death ligand 1 (PD-L1) axis in solid
tumours.193,194 Exhausted T cells express increased levels of
inhibitory immune checkpoint molecules, such as PD-1, CTLA-4,
LAG3 and TIM3,195 and decreased levels of the adhesion/
costimulatory molecule CD2, both of which might attenuate
anti-tumour T-cell responses in tumours.196 However, some
subsets of exhausted T cells that express the transcription factor
TCF1, also known as precursor exhausted T cells,197 display self-
renewing capacity and are essential for the long-term main-
tenance of persistent T-cell responses in different solid
tumours.198–200 The enrichment of this subpopulation during TIL
expansion could therefore enhance the efficacy of ACT thera-
pies.189,201
Future efforts to rapidly sort tumour-reactive cells (e.g. those
expressing cell co-stimulatory molecules such as PD-1, 4-1BB or
OX40)59,191,202 or metabolically ‘fit’ T cells203 might reduce the loss
of efficacy seen in response to high-dose IL-2 culture conditions
and improve the persistence of the T-cell product in vivo. Future
technological advances that can integrate sensitivity into high-
throughput approaches are warranted for the selection of a TIL
product with better anticancer characteristics.48,204,205
So far, T cells in the earliest stages of differentiation (naive or
central memory) have shown the highest efficacy and persistence
in TIL-ACT regimens, as progressive terminal T-cell differentiation
or exhaustion causes loss of anti-tumour power through impair-
ments in TCR signalling and/or via reductions in either cytolytic
activities or adhesion.206,207 However, although the isolation from
patients’ blood of less-differentiated T-cell subsets can be an
effective strategy for generating superior TCR or CAR-engineered
T-cell products, it is more challenging when using TILs, which are
often found in a state of senescence and functional exhaus-
tion.208,209 Moreover, early states of T-cell differentiation might
also coincide with a decreased expression of tissue homing
molecules and trafficking potential, and a less preferential
expansion of TRM T cells.210 Thus, preventing this kind of cellular
fatigue (exhaustion), alongside manipulation of other molecular
pathways, will help to unleash the potential of TIL-ACT for the
treatment of solid tumours.211
Ex-vivo modulation of the TME. As mentioned above, the
enrichment of TILs with better functional activity could potentially
be obtained during the ex vivo expansion stage of the process.
Notably, the TME was also able to be manipulated ex vivo by the
direct application to cultured fragments of breast and ovarian
cancer of the agonistic anti-CD137 antibody, which increased the
rate of TRM-TIL outgrowth; and ICB has been shown to increase
the polyclonal expansion of infiltrating CD8+ TILs and activation
levels of the final T-cell product.212,213 Furthermore, the addition
to expanding TILs of synthetic peptide pools of all predicted HLA-
class I neoantigens improved conventional methods of TIL
generation by enriching for neoantigen-specific CD8+ TILs.59
The use of epigenetic therapies in this ex vivo setting could
increase the expression of transcriptionally repressed neoantigens
and CTA,214 which could potentially enhance the recognition of
cancer cells by adaptive immune cells.215,216 Similarly, epigenetic
therapies could reverse the T-cell chromatin conformation and
DNA methylation that are linked to decreased chemokine
production, T-cell differentiation and exhaustion.217–219 Potential
strategies to reprogramme the T-cell metabolic state ex vivo to
improve T-cell phenotypes also exist.220,221 Treating expanding
T cells with increased levels of extracellular potassium and acetate
resulted in the generation of T cells with retained stemness,
evidenced by self-renewal and multipotency.222 Other strategies
have explored the inhibition of T-cell exhaustion by reducing
mitochondrial oxidative stress,223,224 the reversal of T-cell senes-
cence by inhibiting sestrin complexes.225
Immune-cell engineering. Notably, the time required to expand
TILs could also be used as a ‘window of opportunity’ for immune-cell
engineering with viral vectors226–228 or for gene editing with
CRISPR–Cas9 technology.229 Loss-of-function studies in T cells have
identified genes that, when deleted, can enhance T-cell
responses,230–234 such as p38 MAPK (MAPK14).235 Many groups
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are also investigating whether candidate transcription factors, such
as c-Jun,236 or synthetic cell receptors,237,238 such as the IL-2
receptor,239 can be overexpressed to reprogramme T cells, prevent
exhaustion, or convert suppressive extracellular signals into activat-
ing signals. A first-in-human Phase 1 clinical trial of multiplex
CRISPR–Cas9 gene editing in T cells from three patients with
advanced, refractory cancer (two patients with myeloma and one
with sarcoma) demonstrated that this approach is safe and
feasible.240 T cells engineered using CRISPR–Cas9 editing to express
a synthetic, cancer-specific TCR transgene and to lack expression of
PD-1 persisted for longer than T cells retaining the expression of the
endogenous TCR and PD-1. The gene editing and synthetic
immunology areas are rapidly expanding, and universal approaches
such as ‘off-the-shelf’ T cells (using T cells from healthy donors)
generated through the editing of TCR could substantially advance
the field and dramatically increase the number of patients eligible
for cell therapies241 (Fig. 2d). Advances in protein engineering also
hold promise. The expression of an orthogonal mutant IL-2 receptor
and administration of its paired orthogonal mutant IL-2 ligand
activates only the engineered T cells and not the IL-2 dependent
CD4+Foxp3+ subpopulation of regulatory T (TREG) cells,
242,243 which
have been shown to decrease the therapeutic effect of ACT244
(Fig. 2d). Similarly, an engineered IL-2R agonist that preferentially
reduces IL-2 binding to CD25 (low-affinity IL-2R, highly expressed in
TREG cells) over CD122/CD132 (high-affinity IL2R)
245 was able to
selectively expand intratumoural effector T cells over TREG cells and
synergise with anticancer vaccination.246
The 2020 description of the structure and composition of
cytotoxic multiprotein complexes called supramolecular attack
particles (SMAPs) released by CD8+ effector T cells (cytotoxic T
lymphocytes; CTLs) and natural killer (NK) cells might open
important avenues for ACT.247 SMAPs, which are composed of a
core of cytotoxic proteins such as granzyme B and perforin and a
shell of glycoproteins including thrombospondin-1, are a distinct
type of extracellular particle of ~100 nm in diameter released by
immune cells.247,248 Ideally, the innate specificity of these particles
would be re-engineered towards an individual tumour and
potentially HLA type, enabling the targeting of neoantigen-
expressing tumour cells, potentially by grafting relevant TCRs onto
their surfaces.
Several approaches exist that might, therefore, allow the






































Fig. 3 ATMP manufacturing chain and challenges. The chain starts with the cell-therapy team providing direct patient care. After apheresis
or biopsy collection at the cell-therapy hospital, the material is anonymised, and the relevant setting is required to maintain a chain-of-
custody tracking. The governance and administration team oversee the cell-therapy programme, the development and management of
standard operating procedures, the outcomes of auditing processes as well as assess resource allocation and business planning. The biopsy
sample is processed and transported to the manufacturing facility with a system to ensure that the integrity and chain-of-custody of the initial
cellular material are maintained. At the manufacturing facility (centralised or decentralised), manufacturing specialists in GMP procedures with
expertise in the standardisation of cell-therapy protocols are needed. Clean room requirements are determined by the use of open versus
closed systems. A cell-product storage facility along with electronic database infrastructure for health record documentation and quality
reporting preparation of manufactured products with a chain-of-custody are required. Transport of the cell product back to the hospital
requires temperature and storage controls to maintain viability. In the hospital/organisation, a financial service dealing with single-case
insurance agreements and institutional payer relations is required. A legal and compliance team overseeing the manufacturer contractual
agreements, the interfaces with commercial manufacturers, as well as regulatory assessment for potential international trials, is also required.
Similarly, staff education to provide proper clinical training and scientific and regulatory competencies (cell-therapy fellowships) are required.
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better tumour selectivity, better tumour access capabilities, and
increased activity in an immunosuppressive context. However, these
approaches must meet rigorous quality control and regulatory
qualification processes that account for the risk of off-target
genome-editing modifications.
CHALLENGES IN DELIVERING PERSONALISED ATMPS
The promise of cell therapeutics for cancer treatment comes with
new challenges in the form of reproducible manufacturing and in
administering the product to thousands of patients,249 which
requires the development of high-throughput and robust
methodologies with high fidelity in a timely and GMP manner
for therapeutic applications.250 Therefore, beyond the success of
current clinical trials, commercial-scale cell therapeutics in cancer
might not be available for many patients, simply due to a lack of
capacity to deliver cell therapies. The associated logistical and
economic factors—including physical space, production time,
human resources, consumables and waste generation (and its
environmental impact)—as well as other direct costs, are not
trivial. All these factors must be integrated into the long-term view
of a manufacturing blueprint.251
The application of cell therapy requires not only the manu-
facturing but also the distribution within a regulatory framework
to ensure safety and efficacy. This framework also includes
upstream events such as procurement of starting materials and
the downstream storage and distribution of the product. The
efficacy and stability of the final product are dependent on these
processes, as they are on the rest of the key manufacturing
process.252
Commercial production of cell-therapy products
Traditional manufacturing operations for human therapeutics are
based on the ‘batch’ concept, in which the therapeutic is available
‘off the shelf’ for a large well-defined patient population. ATMPs
instead target specific groups of patients or even individual
patients using a sensitive live-cell therapeutic product. Efficient
commercial production cannot therefore be achieved using the
traditional processes implemented for biopharmaceuticals.
Although many unit operations are similar, generating a cell-
therapy product requires additional processing steps, such as cell
selection, purification, formulation, preservation and distribution,
all of which pose different technical challenges to those needed
for the production of a molecular agent, especially in light of the
number of modifications that cells are required to undergo
(Fig. 3).253
The first consideration is that the recruitment of suitable
patients to receive ACT is critical, particularly to TIL-therapy. The
trial population should be carefully defined with a benefit–risk
balance that should be positive at both a trial and an individual
level. Patient recruitment for cell-based therapy treatments at an
earlier stage, potentially before the use of ICB or other
immunotherapies to ensure the presence of a polyclonal TCR
repertoire in TILs or less senescent TILs,199 could facilitate the
delivery of improved cellular products and minimise complicating
co-morbidities that are associated with advancing metastatic
cancer.47
Manufacturing challenges in the ATMP pipeline
The issue of centralised versus small-scale/hospital manufacturing
has been discussed elsewhere.254–256 However, in both cases, the
production of patient-specific cell therapies presents unique
challenges not seen in the manufacture of pharmaceuticals or
biologicals.
Several academic hospitals worldwide have started to build
their own cell-therapy programmes along with their own in-house
manufacturing capacity.256,257 However, as only pharmaceutical
companies have historically possessed the required
manufacturing expertise to drive late-stage product development
and manufacturing, government-funded initiatives to support the
growth of cell-therapy organisations by bridging the gap between
scientific research (academia) and full-scale commercialisation
(industry) are warranted.
Analytics. As mentioned, rather than scaling-up to increase the
batch size (and thus gain efficiency in the process), the processes
supporting cell therapies need to be ‘scaled out’ to deliver a large
number of individual batches.258 Therefore, with each dose
representing a separate batch, the requirements for records,
quality control (QC) testing, and quality assurance (QA) release
must be repeated for every patient. The QC steps for cell therapy
aim to ensure that the cell product is maintained bioburden-free
and to verify the characteristics of the therapeutic product, such as
identity, purity, activity, functionality, geno-/pheno-typic changes
of the cells and the biocompatibility of the cell products, as well as
other factors such as the culture medium. Developing new
analytical technologies that will support in-process and the release
of a high number of batches (by multiplexing QC tests) will be
needed.259
Biological safety and standards. The provision of a sufficiently
high degree of assurance that the environment does not
contaminate each batch is of course necessary. A comprehensive
analysis of previously unpublished industry-wide viral contamina-
tion information showed how viral infection of cell culture poses a
real risk, particularly for cell therapy. In the context of ATMPs,
safety relies almost exclusively on preventing contamination by
using rigorous process controls.260 For these reasons, as cell
therapies continue to advance quickly towards the clinic, the need
to engineer robust, sustainable and cost-effective manufacturing
processes becomes increasingly important.261–263
The biological activity of the raw materials used for cell
expansion (e.g. cytokines) is of paramount importance as this
can significantly alter the potency and safety profile of cell
products and have significant implications on clinical outcomes.
Indeed, as previously mentioned, various groups are testing
different sources of materials and cytokine mixture to improve cell
expansion and isolation. However, the range of approaches and
assays to test T-cell efficacy against autologous tumours, the
variation in processes and the various equipment used could
hamper comparability and cross-validation of data.259 Consensus
best practices and measurement assurance guidelines must thus
be developed along with eventual standards.
Automation. Several closed automated systems have been
developed to reduce the need for a higher class of cleanroom
and labour-intensive processes that limit the supply, demand high
production costs, and ultimately hinder investments. Functionally
closed systems enable the appropriate degree of sterility and
automation needed and allow the implementation and modula-
tion of the product on a GMP level.264 The industrialisation of
these operations on a small-scale level through robotics and novel
types of equipment will provide, on a single platform, the
necessary scalability, by parallel processing of multiple patient
batches, for large clinical trials263,265 It will also allow the
manufacturing of multiple personalised products within a small
sized GMP facility.256 With the need to select a high number of
specific cell subtypes for neoantigen-TIL therapy, future techno-
logical improvement of cell-sorting instruments at GMP grade is
also required.
Qualified personnel and accredited centres. One of the main
challenges for the success of a cell therapy programme will be the
availability of qualified personnel sufficiently trained in the
processes and operations of a GMP facility. A 2017 survey
established there were approximately 500 roles in bioprocessing
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in the UK, while a similar 2019 survey demonstrated significant
growth beyond the expected forecast, with current bioprocessing
employment at >1,700 roles; this figure is forecast to reach over
3,800 by 2024 in the UK.266 Existing academic initiatives, as well as
new bridges between academia and industry for training, need to
be expanded to meet the current demand for GMP manufacturing
specialists.266,267
Another critical point is the designation of cell-therapy
accredited centres that have shared and agreed clinical and
laboratory standards of excellence.268 Cell-therapy programmes
require specialised professional multidisciplinary teams that are
focussed on addressing the complex infrastructure and patient
care needs inherent to such programmes.269 The incorporation of
a structured audit as a requirement for accreditation is warranted
due to the high standards required for successful cell-therapy
programmes.270
Transport and storage. A key consideration is transport, which
can have a significant impact on the product’s viability. The
transport of newly harvested biological materials to a manufactur-
ing centre close to the collection point simplifies the logistics and
in parallel decreases the risks related to the deterioration of
cellular product quality and integrity.267,271 In addition, for
transportation to a central manufacturing facility, the issues for
data inventory, packaging, and tracking become even more
critical.
The need to store cellular material or conserve particular cellular
attributes, often at several points during the manufacturing and
transportation processes, necessitates the optimisation of cryo-
preservation of cell-therapy products, as these products are highly
susceptible to temperature fluctuations. Suboptimal cryopreserva-
tion can lead to batch-to-batch variation, lowered cellular
functionality and reduced cell yield.272,273 Further research and
development, as well as the establishment of regulatory guide-
lines, will be required to ensure robust and reproducible
approaches to the freezing, storage and thawing of the
product.274
Challenges for the widespread availability of ATMPs
The Food and Drug Administration projected that by 2025 it
would be approving between 10 and 20 new cell and gene
therapy products a year with more than 40 of these therapies
potentially available on the market in the next five years. The
incorporation of cell and gene therapy as a new therapeutic
strategy, along with surgery, chemo and radiotherapy, will
determine critical new challenges in the clinical practice. In fact,
the complexity of these treatments is not limited only by
manufacturing issues, but also by a new paradigm shift in cancer
treatment, where the patients and hospital personal are part of
the supply chain with all the training, ethical and legislative issues
connect it.
Personnel, networks and communication. The transition from
drug-based clinical trials to a growing number of cell therapy
trials will also increase the need for skilled clinicians in the field
of ATMPs, both from a scientific and regulatory point of view.
Cellular therapy fellowships are starting to be advertised in the
USA and will probably be implemented worldwide. These
schemes should not be restricted to immuno-oncologists but,
rather, should aim to create multidisciplinary teams comprising
surgeons, interventional radiologists and other allied specialists
dedicated to cell therapy programmes. A critical step in this
direction would be to establish specialised treatment centres for
ATMPs that enable networking activities between manufactur-
ing units, specialised contractors, academic research, clinical
centres, patients and caregivers. These networked clinical
environments would also facilitate new business models, in
which decision-making, cost, and risk of establishing efficacy,
safety and quality are shared through an infrastructure that links
data across cell-therapy professionals and stakeholders at all
stages of development.275 These networked clinical environ-
ments will also provide an opportunity to address the evidence
requirements for licensure and reimbursement, allowing stake-
holder connectivity around post-authorisation commitments.
The need to actively involve/engage patients/patient groups as
key stakeholders in discussions around the development of
ATMPs will be crucial. Support and information should be
available for patients—and caregivers—undergoing treatment
with ATMPs. Patients should be fully informed about the
treatment and its effects through discussion with a healthcare
professional and provision of patient resources.
Access to ATMPs. It should be acknowledged that access to
ATMPs is likely to be a particular challenge for patients,
healthcare professionals and national health systems, owing to
their expected high costs. In particular, the cost of ACT using
mutation-reactive T cells can be several times that of CAR-T cell-
based immunotherapy.47 Not surprisingly, access to haemato-
poietic stem-cell transplantation is still associated with higher-
income countries only.276 Although a discussion of the
reimbursement aspect of ATMPs is outside the scope of this
review, ensuring equitable access to cell therapies, from a
financial and geographical point of view, and managing
expectations and patient demands for access to therapeutics
with high potential but as-yet-unproven interventions are
important topics.277
Ethics and regulatory requirements. Professional communities
should also promote the adoption of standards that meet the
arising associated ethical considerations. An integrated ethical
approach that aims for transparency and regulation of devel-
opment processes, the support of independent judgement and
the elimination of unregulated and uncontrolled grey areas of
action are necessary to move cell therapy forward.278 Therefore,
national and international societies should make readily
available up-to-date information on accredited centres to
minimise the risk of unproven and unethical interventions to
patients.279
International co-ordination in the harmonisation of regulatory
requirements is warranted because of potential future multi-
centre ATMP trials. In fact, specific regulations still vary by
nation: for example, in the European Union and Switzerland,
GMP requirements are expected for all stages of clinical trials
(including Phase 1 trials where most novel ATMPs are located),
but this is not the case in the USA.253,280 Regulations and
standards must also evolve to reflect products that are
personalised and sometimes administered in settings of urgent
medical need.281 Ideally, these initiatives should be led by an
umbrella of international societies to avoid duplication of
effort.282–284
CONCLUSIONS
The field of ACT is growing exponentially. However, despite the
complete and durable responses seen in some patients with late-
stage and treatment-refractory diseases, a subset of patients do
not respond, might relapse, or do not have an adequate ACT
strategy for their disease.285 New strategies and ideas are needed
to enhance T-cell efficacy and reduce exhaustion, to circumvent
TME immunosuppression and to optimise T-cell manufacturing.
Future translational efforts might open the way for combinational
or sequential therapies with ACT-TIL. Parallel processes are
required to establish treatment centres, modernise regulatory
and commercialisation approaches and to effectively deal with
arising ethical considerations. The involvement of all stakeholders,
including patient representatives, will be essential to ensure the
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successful translation of cell-therapy research to clinical
implementation.
Here, we have reviewed the three pillars of ACT—cancer
genomics, cancer–immune system interactions and cell therapy
manufacturing—and discussed ongoing research efforts in these
fields that will hopefully broaden the application of ACT to many
cancer types. The integration of new genome-engineering or
genome-editing technologies such as CRISPR into cell therapies
might lead to significant progress.286
Issues of scale-up, automation and commercialisation that are
unique to ACT need to be addressed to create the infrastructure
required for the widespread availability of cell-therapeutics
strategies. Finally, new models of academia–industry collaboration
will be required. We argue/believe that overcoming the challenges
facing ACT in such processes has the potential to improve clinical
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